These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 22949142)

  • 61. Eplerenone reduces morbidity and mortality after acute MI.
    Cardiovasc J S Afr; 2006; 17(5):280. PubMed ID: 17117244
    [No Abstract]   [Full Text] [Related]  

  • 62. The risks and benefits of aldosterone antagonists.
    Sica DA
    Curr Heart Fail Rep; 2005 Aug; 2(2):65-71. PubMed ID: 16036053
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? Aldosterone receptor antagonists?
    van der Horst IC; Voors AA; van Veldhuisen DJ
    Clin Res Cardiol; 2007 Apr; 96(4):193-5. PubMed ID: 17294352
    [No Abstract]   [Full Text] [Related]  

  • 64. Race influences the safety and efficacy of spironolactone in severe heart failure.
    Vardeny O; Cavallari LH; Claggett B; Desai AS; Anand I; Rossignol P; Zannad F; Pitt B; Solomon SD;
    Circ Heart Fail; 2013 Sep; 6(5):970-6. PubMed ID: 23940307
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Optimization of heart FailUre medical Treatment after hospital discharge according to left ventricUlaR Ejection fraction: the FUTURE survey.
    Cohen Solal A; Leurs I; Assyag P; Beauvais F; Clerson P; Contre C; Thebaut JF; Genoun M;
    Arch Cardiovasc Dis; 2012; 105(6-7):355-65. PubMed ID: 22800720
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Aldosterone-receptor antagonists in heart failure: insights after EMPHASIS-HF.
    Jacob MS; Tang WH
    Curr Heart Fail Rep; 2011 Mar; 8(1):7-13. PubMed ID: 21207206
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Misdiagnosed emergency: heart failure symptoms after infarct. Rapid aldosterone block can safe the tired heart].
    MMW Fortschr Med; 2008 May; 150(22):48-9. PubMed ID: 18700263
    [No Abstract]   [Full Text] [Related]  

  • 68. The safety of spironolactone treatment in patients with heart failure.
    Anton C; Cox AR; Watson RD; Ferner RE
    J Clin Pharm Ther; 2003 Aug; 28(4):285-7. PubMed ID: 12911680
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Impact of Hyperkalemia and Worsening Renal Function on the Use of Renin Angiotensin Aldosterone System Inhibitors in Chronic Heart Failure With Reduced Ejection Fraction.
    Pitt B; Rossignol P
    Clin Pharmacol Ther; 2017 Sep; 102(3):389-391. PubMed ID: 28707341
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Spironolactone in chronic hemodialysis patients improves cardiac function.
    Taheri S; Mortazavi M; Shahidi S; Pourmoghadas A; Garakyaraghi M; Seirafian S; Eshaghian A; Ghassami M
    Saudi J Kidney Dis Transpl; 2009 May; 20(3):392-7. PubMed ID: 19414940
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Mineralocorticoid Antagonists in ESRD: An Overview of Clinical Trial Evidence.
    Georgianos PI; Vaios V; Eleftheriadis T; Zebekakis P; Liakopoulos V
    Curr Vasc Pharmacol; 2017; 15(6):599-606. PubMed ID: 28155610
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Evolving strategies for the use of spironolactone in cardiovascular disease.
    Jolobe OM
    Eur J Intern Med; 2013 Jun; 24(4):303-9. PubMed ID: 23245930
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Treatment of Hyperkalemia in Heart Failure.
    DeFilippis EM; Desai AS
    Curr Heart Fail Rep; 2017 Aug; 14(4):266-274. PubMed ID: 28656517
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effect of Mineralocorticoid Receptor Antagonists in Heart Failure with Preserved Ejection Fraction and with Reduced Ejection Fraction - A Narrative Review.
    Mares A; Rodriguez T; Deoker A; Lehker A; Mukherjee D
    Curr Vasc Pharmacol; 2022; 20(1):46-51. PubMed ID: 34303331
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Inspra improves survival for CHF patients.
    Wimett L; Laustsen G
    Nurse Pract; 2004 Jul; 29(7):56-9. PubMed ID: 15238861
    [No Abstract]   [Full Text] [Related]  

  • 76. Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure.
    Nappi JM; Sieg A
    Vasc Health Risk Manag; 2011; 7():353-63. PubMed ID: 21731887
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Serious adverse events experienced by patients with chronic heart failure taking spironolactone.
    Berry C; McMurray JJ
    Heart; 2001 Apr; 85(4):E8. PubMed ID: 11250985
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure.
    Sica DA
    Methodist Debakey Cardiovasc J; 2015; 11(4):235-9. PubMed ID: 27057293
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Mineralocorticoid Receptor Antagonists in the Management of Heart Failure and Resistant Hypertension: A Review.
    Flatt DM; Brown MC; Mizeracki AM; King BJ; Weber KT
    JAMA Cardiol; 2016 Aug; 1(5):607-12. PubMed ID: 27434136
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Recent developments in the management of heart failure.
    Cowie MR
    Practitioner; 2012 Jun; 256(1752):25-9, 3. PubMed ID: 22916582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.